Covered recipient · General Payments record
MARTHA GROGAN
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
General Payments · PY2018–2024
$343,510.98
- Reported across 79 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $33,948.50 | 6 |
| Travel and Lodging | $6,853.14 | 3 |
| Food and Beverage | $8.65 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | $20,455.00 | 1 |
| Novo Nordisk AS | $12,696.16 | 4 |
| Janssen Research & Development, LLC | $4,040.00 | 1 |
| AstraZeneca UK Limited | $2,148.00 | 2 |
| Acerta Pharma LLC | $805.50 | 1 |
| PFIZER INC. | $665.63 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $20,455.00 | 12/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1125837947 | CMS |
| AstraZeneca Pharmaceuticals LP | $805.50 | 05/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105597687 | CMS |
| AstraZeneca UK Limited | $1,611.00 | 02/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093999282 | CMS |
| AstraZeneca UK Limited | $537.00 | 06/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093894347 | CMS |
| Janssen Research & Development, LLC | $4,040.00 | 09/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1077589447 | CMS |
| Novo Nordisk AS | $5,601.15 | 05/13/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096552657 | CMS |
| Novo Nordisk AS | $586.36 | 05/13/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096552805 | CMS |
| Novo Nordisk AS | $8.65 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096552939 | CMS |
| Novo Nordisk AS | $6,500.00 | 05/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096553111 | CMS |
| PFIZER INC. | $665.63 | 01/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1131169836 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.